Abstract Background: Severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infection is a recently emerged viral infection causing predominantly mild upper respiratory symptoms. However, in some instances, it might result in acute respiratory distress syndrome (ARDS) that poses a significant mortality risk. ARDS is postulated to be mediated by a surge of pro-inflammatory cytokines and chemokines, leading to a dysregulated hyper inflammatory response. Colchicine being an anti-inflammatory agent, might mitigate this dysregulated response. Thus, in the absence of therapeutic options available to manage coronavirus disease 2019 (COVID-19), it is imperative to ascertain the effect of colchicine on improving outcomes in COVID-19 patients. Method: We will perform a systematic review including a search of the following databases: PubMed, EMBASE, MEDLINE, Clinicaltrials.gov, Cochrane library, and google scholar since inception. We will include randomized controlled trials exploring the effect of colchicine on the efficacy and safety outcomes of COVID-19 patients. Subsequently, we will perform a meta-analysis utilizing the random-effects to ascertain the effect of colchicine on reducing COVID-19 related mortality (primary endpoint) and other efficacy and safety outcomes. Results: Our review results are anticipated in early 2021 (based on the completion of several ongoing randomized controlled trial). Our review results will be published in a peer-reviewed journal. Conclusion: This systematic review and meta-analysis, is exploring the effect of colchicine on the efficacy and safety outcomes of COVID-19 patients. If colchicine proved to be effective, it would be a significant milestone in the management of COVID-19, a disease with limited available therapeutic options. PROSPERO registration number: CRD42020191086
【저자키워드】 severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019, Mortality, Colchicine, 【초록키워드】 COVID-19, Randomized controlled trial, coronavirus disease, Meta-analysis, viral infection, ARDS, coronavirus, Infection, systematic review, chemokines, outcome, outcomes, management, Mild, Efficacy and safety, disease, COVID-19 patients, therapeutic options, acute respiratory distress, mortality risk, Inflammatory response, primary endpoint, therapeutic option, upper respiratory symptoms, anti-inflammatory agent, acute respiratory syndrome, syndrome, pro-inflammatory cytokine, COVID-19 related mortality, instances, mitigate, effective, include, absence, reducing, imperative, dysregulated, peer-reviewed, anticipated, dysregulated response, random-effect, 【제목키워드】 coronavirus disease, Meta-analysis, Efficacy, protocol, systematic review, management,